logo

For the Inventor, By the Inventor

Plainsboro, NJ, United States of America

Xiaoqiang Kang

This inventor holds 8 USPTO granted patents and 1 published patent application. Top assignees: Nanjing Leads Biolabs Co., Ltd., Imclone LLC, Nanjing Leads Biolabs Co., Ltd.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoqiang Kang. Retrieved from https://idiyas.com/inventor/xiaoqiang-kang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 75.0

Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Plainshoro, NJ (US) (2021)
  • Plainsboro, NJ (US) (2011 - 2024)

Company Filing History:

goldMedal6 out of 6 
 
Nanjing Leads Biolabs Co., Ltd.
 patents
silverMedal1 out of 26 
 
Imclone LLC
 patents
bronzeMedal1 out of 1 
 
Nanjing Leads Biolabs Co., Ltd.
 patent

Years Active: 2011-2026

Loading Chart...
8 patents (USPTO):Explore Patents
1. 12723086 - ANTIBODIES BINDING 4-1BB AND USES THEREOF (2026-09-01),
2. 11912777 - Antibodies binding TNFR2 and uses thereof (2024-02-27),
3. 11807683 - Antibody binding TIM-3 and use thereof (2023-11-07),
4. 11802145 - Recombinant protein targeting PD-1 and TGFß (2023-10-31),
5. 11466086 - Antibodies binding 4-1BB and uses thereof (2022-10-11),
6. 11136394 - Antibody binding PD-1 and use thereof (2021-10-05),
7. 10844121 - Antibodies binding LAG-3 and uses thereof (2020-11-24),
8. 7951370 - Anti-TYRP1 antibodies (2011-05-31),

Title: Innovations of Xiaoqiang Kang

Introduction

Xiaoqiang Kang is a prominent inventor based in Plainsboro, NJ, known for his significant contributions to the field of biotechnology. He holds a total of seven patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents is the invention titled "Antibodies binding TNFR2 and uses thereof." This invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2. It also includes a composition comprising the antibody or antibody fragment, a nucleic acid encoding the antibody, and a host cell containing the same. The invention further explores the use of the antibody and antibody fragment for treatment and diagnosis. Another notable patent is "Antibody binding TIM-3 and use thereof," which provides an isolated monoclonal antibody that specifically binds human TIM-3. This patent also includes a pharmaceutical composition comprising the antibody and its various uses.

Career Highlights

Xiaoqiang Kang has worked with several notable companies throughout his career, including Nanjing Leads Biolabs Co., Ltd. and Imclone LLC. His experience in these organizations has contributed to his expertise in developing innovative biotechnological solutions.

Collaborations

He has collaborated with several professionals in his field, including Xiao Huang and Shoupeng Lai. These collaborations have likely enhanced his research and development efforts.

Conclusion

Xiaoqiang Kang's work in biotechnology, particularly in the development of antibodies for therapeutic uses, highlights his role as a key innovator in the industry. His patents reflect a commitment to improving medical treatments and diagnostics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…